Copyright
©The Author(s) 2015.
World J Gastroenterol. Jun 7, 2015; 21(21): 6470-6478
Published online Jun 7, 2015. doi: 10.3748/wjg.v21.i21.6470
Published online Jun 7, 2015. doi: 10.3748/wjg.v21.i21.6470
RCC | LCC | ||
Survival | |||
5-yr OS in 1990s | 56.3% | 59.7% | P < 0.01 |
in 2000s | 67% | 71% | P < 0.01 |
5-yr DFS in 2010 | 73% | 74% | P > 0.05 |
in 2014 | 88.6% | 89.4% | P > 0.05 |
Median OS (mo) | 18.2% | 29.4% | P < 0.001 |
Dominant treatment - Adjuvant | FOLFIRI | FOLFOX | |
Palliative | Anti-EGFR therapy | Anti-angiogenesis | |
Molecular levels | |||
Carcinogenesis mechanisms | MMR, KRAS, BRAF, miRNA-31 | CIN (p53), NRAS; miRNA-146a, 147b, 1288 | |
Protein expressions | GNAS, NQO1, Telomerase, p-PDH | ANXA10, Topo I, | |
TS, EGFR | |||
Relapse pathways | Cell cycle control genes, high WNT signaling | Stromal expression, low WNT signaling | |
Prognostic biomarkers | CDX2, ITGA3 | NOX4 |
- Citation: Shen H, Yang J, Huang Q, Jiang MJ, Tan YN, Fu JF, Zhu LZ, Fang XF, Yuan Y. Different treatment strategies and molecular features between right-sided and left-sided colon cancers. World J Gastroenterol 2015; 21(21): 6470-6478
- URL: https://www.wjgnet.com/1007-9327/full/v21/i21/6470.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i21.6470